These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15051054)

  • 1. New chemical adaptor unit designed to release a drug from a tumor targeting device by enzymatic triggering.
    Gopin A; Rader C; Shabat D
    Bioorg Med Chem; 2004 Apr; 12(8):1853-8. PubMed ID: 15051054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical adaptor systems.
    Shabat D; Amir RJ; Gopin A; Pessah N; Shamis M
    Chemistry; 2004 Jun; 10(11):2626-34. PubMed ID: 15195294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.
    Gopin A; Pessah N; Shamis M; Rader C; Shabat D
    Angew Chem Int Ed Engl; 2003 Jan; 42(3):327-32. PubMed ID: 12548691
    [No Abstract]   [Full Text] [Related]  

  • 4. A new probe for targeting drug delivery system.
    Yu Z; Wang B; Sui J; Feng Y; Zheng C
    Med Hypotheses; 2009 Jan; 72(1):43-4. PubMed ID: 18829175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a new enzyme-responsive self-immolative spacer conjugate applicable to the controlled drug release.
    Jin HJ; Lu J; Wu X
    Bioorg Med Chem; 2012 Jun; 20(11):3465-9. PubMed ID: 22564382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prodrug strategies in anticancer chemotherapy.
    Kratz F; Müller IA; Ryppa C; Warnecke A
    ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
    Ojima I
    Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?
    Juillerat-Jeanneret L
    Drug Discov Today; 2008 Dec; 13(23-24):1099-106. PubMed ID: 18848640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo release from a drug delivery MEMS device.
    Li Y; Shawgo RS; Tyler B; Henderson PT; Vogel JS; Rosenberg A; Storm PB; Langer R; Brem H; Cima MJ
    J Control Release; 2004 Nov; 100(2):211-9. PubMed ID: 15544869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical mechanisms and methods employed in drug delivery to tumors.
    Besić E
    Acta Pharm; 2007 Sep; 57(3):249-68. PubMed ID: 17878107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME).
    Tanaka T; Shiramoto S; Miyashita M; Fujishima Y; Kaneo Y
    Int J Pharm; 2004 Jun; 277(1-2):39-61. PubMed ID: 15158968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting the enhanced permeability and retention effect for tumor targeting.
    Iyer AK; Khaled G; Fang J; Maeda H
    Drug Discov Today; 2006 Sep; 11(17-18):812-8. PubMed ID: 16935749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective induction of tumor ischemia: development of vascular targeting agents for cancer therapy.
    Chaplin DJ; Hill SA
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1381-4. PubMed ID: 12498016
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumour-targeted drug and gene delivery: principles and concepts.
    Cassidy J; Schätzlein AG
    Expert Rev Mol Med; 2004 Sep; 6(19):1-17. PubMed ID: 15387893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
    Maeda H; Bharate GY; Daruwalla J
    Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members.
    Verdine GL; Walensky LD
    Clin Cancer Res; 2007 Dec; 13(24):7264-70. PubMed ID: 18094406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer drug delivery with nanoparticles.
    Conti M; Tazzari V; Baccini C; Pertici G; Serino LP; De Giorgi U
    In Vivo; 2006; 20(6A):697-701. PubMed ID: 17203748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticles of biodegradable polymers for new-concept chemotherapy.
    Feng SS
    Expert Rev Med Devices; 2004 Sep; 1(1):115-25. PubMed ID: 16293015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle and targeted systems for cancer therapy.
    Brannon-Peppas L; Blanchette JO
    Adv Drug Deliv Rev; 2004 Sep; 56(11):1649-59. PubMed ID: 15350294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.